戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 C(5) configuration (equivalent to (1)C(4) in aldoses).
2  of D-[1-(13)C]aldose and D-[1-(13)C; 1-(2)H]aldose.
3 nary center, starting from readily available aldoses.
4 ins all the conserved amino acids within the aldose 1-epimerase protein motif.
5                                              Aldose-1-epimerase (mutarotase) catalyzes the interconve
6 rases from bacteria, and no gene encoding an aldose-1-epimerase has been isolated previously from hig
7 rs and is effected by the enzyme mutarotase (aldose-1-epimerase).
8 y, gp40 has 28 to 34% amino acid identity to aldose-1-epimerases from bacteria, and no gene encoding
9    The greatest sequence similarity was with aldose-6-phosphate reductase (EC 1.1.1.200), a key enzym
10                                              Aldose, aldehyde, and glyceraldehyde reductases are pres
11  containing equimolar mixtures of D-[1-(13)C]aldose and D-[1-(13)C; 1-(2)H]aldose.
12 Hydrogen atom transfer reactions between the aldose and ketose are key mechanistic features in formos
13 C. 5.3.1.5) catalyzes the interconversion of aldose and ketose sugars and has an absolute requirement
14 nterconversion of alpha- and beta-anomers of aldoses and is a recently identified member of the gal o
15 ere a complex mixture of linear and branched aldoses and ketoses are produced.
16 distribution into isotopomers of 13C-labeled aldoses and ketoses, and the fragmentation pathways for
17 sphoenolpyruvate (PEP) and the corresponding aldose: arabinose 5-phosphate (A5P) and erythrose 4-phos
18 l anodes and biosensors capable of oxidizing aldoses as cellobiose as well as lactose and glucose and
19 ears to involve the anomeric position (C1 in aldoses, C2 in ketoses), which has a more acidic hydroxy
20                        Specifically, a 5 wt% aldose (for example, glucose, xylose or arabinose) solut
21 onsible for ring opening of the sugar to the aldose form, an observation that has been difficult to e
22 first step in the assimilation of xylose, an aldose found to be a major constituent monosaccharide of
23 molecular carbon shift (1,2-CS) reactions of aldoses, i.e., various molybdenum oxide and molybdate sp
24 ate catalyses the selective epimerization of aldoses in aqueous media.
25 ecause PMP specifically reacts with reducing aldoses, interference from noncarbohydrate components pr
26                                The enzymatic aldose ketose isomerisation of glucose and fructose suga
27  acceleration for enzymatic catalysis of the aldose-ketose isomerization of (R)-glyceraldehyde 3-phos
28 chment of dihydroxyacetone obtained from the aldose-ketose isomerization of D,L-glyceraldehyde in D(2
29 echanism involves an initial metal-catalyzed aldose-ketose isomerization reaction, which results in t
30 triosephosphate isomerase (TIM) catalyze the aldose-ketose isomerization reactions of D-xylose and d-
31 ng thermal treatment indicated a tripling of aldose-ketose transformation in the presence of l-pyrogl
32 t molecules including phenolics, low pH, and aldose monosaccharides to activate its pathogenic pathwa
33 on refers to the reversible reaction between aldoses (or ketoses) and amino groups yielding relativel
34 ing hyperglycemic and hypertonic stress, the aldose-reducing property of AR has been accepted as its
35                                              Aldose reductase (AKR1B1) is a critical drug target beca
36 es involved in BH(4) biosynthesis, including aldose reductase (AKR1B1), carbonyl reductase (CBR1 and
37 lant, is a potent and selective inhibitor of aldose reductase (AKR1B1).
38                                              Aldose reductase (ALR2) is the first and rate-limiting e
39                                              Aldose reductase (ALR2), a NADPH-dependent aldo-keto red
40 vas deferens protein (MVDP) (76%), and human aldose reductase (AR) (62%).
41 he sodium/myo-inositol cotransproter (SMIT), aldose reductase (AR) and heat shock protein 70 (HSP70)
42 that inhibition of the polyol pathway enzyme aldose reductase (AR) by two structurally unrelated inhi
43 -carboxylic acid, non-hydantoin inhibitor of aldose reductase (AR) capable of potently blocking the e
44                                              Aldose reductase (AR) catalyzes the reduction of several
45  and structural changes in recombinant human aldose reductase (AR) due to modification by S-nitrosogl
46 is study, the selectivity and specificity of aldose reductase (AR) for glutathionyl aldehydes was exa
47             Increased glucose utilization by aldose reductase (AR) has been implicated in the develop
48                                              Aldose reductase (AR) has been implicated in the etiolog
49                                              Aldose reductase (AR) has been implicated in the etiolog
50 ion of glucose via the polyol pathway enzyme aldose reductase (AR) has been linked to the development
51             The study addressed the role for aldose reductase (AR) in 1) retinal oxidative stress and
52         This study examined the functions of aldose reductase (AR) in mediating acute lung inflammati
53 cidate the role of the polyol pathway enzyme aldose reductase (AR) in the mediation of ocular inflamm
54  of this study was to evaluate the effect of aldose reductase (AR) inhibition on posterior capsular o
55                                 Sorbinil, an aldose reductase (AR) inhibitor, attenuated GS-DHN level
56             Our recent studies indicate that aldose reductase (AR) inhibitors such as fidarestat inhi
57 hibition of the aldehyde-metabolizing enzyme aldose reductase (AR) inhibits NF-kappa B activation dur
58                                              Aldose reductase (AR) is a member of the aldo-keto reduc
59                                              Aldose reductase (AR) is a multifunctional enzyme that c
60                                              Aldose reductase (AR) is a multifunctional enzyme that r
61                                              Aldose reductase (AR) is an aldo-keto reductase that has
62 e stress and an earlier study has shown that aldose reductase (AR) mediates oxidative stress signals,
63  Sustained increases in glucose flux via the aldose reductase (AR) pathway have been linked to diabet
64                                          The aldose reductase (AR) polyol pathway contributes to thes
65 y, the authors showed that the inhibition of aldose reductase (AR) prevents bacterial endotoxin-induc
66 that inhibition of the polyol pathway enzyme aldose reductase (AR) prevents the increase in ICAM-1 an
67                                              Aldose reductase (AR) reduces cytotoxic aldehydes and gl
68 rated that, in response to multiple stimuli, aldose reductase (AR) regulates the inflammatory signals
69                                              Aldose reductase (AR) was immunohistochemically localize
70                                 Induction of aldose reductase (AR) was observed in human cells treate
71                                              Aldose reductase (AR), a member of the aldo-keto reducta
72                                              Aldose reductase (AR), a member of the aldo-keto reducta
73                                              Aldose reductase (AR), a member of the aldo-keto reducta
74 e activity and on expression and activity of aldose reductase (AR), a primary enzyme of polyol metabo
75    We have recently shown that inhibition of aldose reductase (AR), an enzyme that catalyzes the redu
76                            The gene encoding aldose reductase (AR), an enzyme that mediates the gener
77 ee enzymes: triosephosphate isomerase (TIM), aldose reductase (AR), and phosphomannose isomerase (PMI
78  glucose were more potent: Inhibiting NOS or aldose reductase (AR), scavenging superoxide or peroxyni
79                                Inhibition of aldose reductase (AR), the first enzyme of the polyol pa
80                                   The enzyme aldose reductase (AR), which is implicated in the regula
81 e studies reported here, we examined whether aldose reductase (AR), which reduces hydrophobic aldehyd
82           Sorbitol synthesis is catalyzed by aldose reductase (AR).
83 rnosine-propanals is catalyzed by the enzyme aldose reductase (AR).
84 r endogenous), its metabolite uric acid, and aldose reductase (AR, the only endogenous enzyme that pr
85 hibition of the aldehyde-metabolizing enzyme aldose reductase (AR; AKR1B3) modulates NF-kappaB-depend
86 ihydroxyphenylethanol (DOPET) by aldehyde or aldose reductase (ARs).
87 transgenic mice broadly overexpressing human aldose reductase (ARTg) driven by the major histocompati
88  effects of reducing both the Km and Vmax of aldose reductase (EC 1.1.1.21), an enzyme whose function
89 hyde reductase (EC 1.1.1.2, Akr1a4 (GR)) and aldose reductase (EC 1.1.1.21, Akr1b3 (AR)) as the enzym
90 drophobic region of the active site of human aldose reductase (hALR2).
91 are enriched in an "activated" form of human aldose reductase (hAR), a NADPH-dependent oxidoreductase
92 and in alcohol oxidation activities of human Aldose reductase (hAR).
93 s alpha-glucosidase (K(i) = 166.9 ug/mL) and aldose reductase (K(i) = 127.5 ug/mL) through non-compet
94             The kinetic parameter of cardiac aldose reductase (Kcat) was significantly higher in isch
95 e sodium/chloride/betaine cotransporter, and aldose reductase (synthesis of sorbitol).
96 ological inhibition or antisense ablation of aldose reductase (which catalyzes the reduction of GS-HN
97 esulted in hyperglycemia, activation of lens aldose reductase 2 (ALR2) and accumulation of sorbitol i
98 models, we report that hyperglycemia-induced aldose reductase activation and subsequent reactive oxyg
99  hyperactivation, mitochondrial dysfunction, aldose reductase activation, reactive oxygen species pro
100                                              Aldose reductase activity and polyols were below our lim
101 monstrate that ischemia increases myocardial aldose reductase activity and that these increases are,
102 ring of blood glucose and inhibition of lens aldose reductase activity because of which there was a c
103                                       Excess aldose reductase activity can be a mechanism for human d
104   The results support the role for increased aldose reductase activity in functional and structural c
105      Diabetic mice, known to have much lower aldose reductase activity in other tissues when compared
106       These data indicate that inhibition of aldose reductase activity preserves high-energy phosphat
107 5); GAPDH activity was higher; and G-3-P and aldose reductase activity were lower.
108 ent, the hexose monophosphate shunt pathway, aldose reductase activity, and levels of sorbitol and ga
109                                The increased aldose reductase activity, higher sorbitol content and l
110          Two distinct peaks corresponding to aldose reductase and aldehyde reductase, the latter bein
111 ORE/TonE reporter activity, and induction of aldose reductase and betaine transporter mRNAs.
112 ic histidine residues in the key proteins in aldose reductase and heat-shock protein-70 within living
113 bitors that are able to discriminate between aldose reductase and other members of the aldo-keto redu
114  mice, glucose consumption is accompanied by aldose reductase and polyol pathway activation in steato
115  data also support the idea of activation of aldose reductase and polyol pathway as an important mech
116                              The presence of aldose reductase and sorbitol dehydrogenase in these cel
117                                     To study aldose reductase and the sorbitol pathway in periodontit
118 inhibitor (zopolrestat) or transfection with aldose reductase antisense oligonucleotide blocked the p
119 inhibitors with the carboxy-terminal loop of aldose reductase are critical for the development of inh
120 eover, osmotic stress response genes such as aldose reductase are not induced upon T cell activation.
121 ed NF-kappaB and increased the expression of aldose reductase but not ICAM-1 and VCAM-1.
122                                  Ablation of aldose reductase by small interference RNA (siRNA) preve
123 tudy show that pharmacological inhibition of aldose reductase by sorbinil or knockdown of the enzyme
124                        Our data suggest that aldose reductase can compensate for the loss of GLO1.
125                                              Aldose reductase catalyzed the reduction of chemically s
126                     The crystal structure of aldose reductase complexed with 13 revealed an interacti
127                                              Aldose reductase contributes to diabetes-mediated mitoch
128 affinity for cofactor than the related human aldose reductase does.
129         A new and essential cis-element AEE (aldose reductase enhancer element), necessary for the co
130             Two representative genes are the aldose reductase enzyme (AR, EC 1.1.1.21), which is resp
131 hat vitamin K1 is a potent inhibitor of lens aldose reductase enzyme and we made an attempt to unders
132 lens homogenate as well as recombinant human aldose reductase enzyme.
133         Transgenic mice overexpressing human aldose reductase exhibited increased JAK2 and STAT5 acti
134 valuated whether soluble uric acid regulates aldose reductase expression both in cultured hepatocytes
135        Uric acid dose-dependently stimulated aldose reductase expression in the HepG2 cells, and this
136 yperuricemic rats exhibited elevated hepatic aldose reductase expression, endogenous fructose accumul
137                                          The aldose reductase gene is controlled by a tonicity-respon
138 , using an ORE.AP-1 reporter from the target aldose reductase gene or the same reporter with a mutate
139                          In the spinal cord, aldose reductase immunoreactivity was present solely in
140 t and human retinal endothelial cells showed aldose reductase immunoreactivity, and human retinas exp
141 ase inhibitor, the presence and influence of aldose reductase in cardiac tissue remain unknown.
142 lic regulation due to increased flux through aldose reductase in diabetic hearts may influence the ab
143  safety; as a result, the pathogenic role of aldose reductase in diabetic retinopathy remains controv
144                                Inhibition of aldose reductase in GLO1(-/-) cells is associated with a
145 d a western blot confirmed a higher level of aldose reductase in mutant mitochondria.
146 further test the possible pathogenic role of aldose reductase in the development of diabetic retinopa
147 ndogenous fructose production by stimulating aldose reductase in the polyol pathway.
148 means of osmotic stress induced by activated aldose reductase in the sorbitol pathway.
149                                Inhibition of aldose reductase increased survival in mice injected wit
150                    Even though inhibition of aldose reductase increases vascular oxidative stress, th
151                                              Aldose reductase inhibited hearts, when subjected to isc
152 nil Retinopathy Trial, a randomized trial of aldose reductase inhibition among patients aged 18-56 ye
153                  The plant was evaluated for aldose reductase inhibition and anti-diabetic action.
154 INSIM, with the conclusion that all reported aldose reductase inhibition can be rationalized in terms
155                               In conclusion, aldose reductase inhibition counteracts diabetes-induced
156                              To determine if aldose reductase inhibition improves tolerance to ischem
157 tion cannot be regarded as an alternative to aldose reductase inhibition in eliminating antioxidant a
158                                              Aldose reductase inhibition increased glycolysis and glu
159          This study evaluated the effects of aldose reductase inhibition on diabetes-induced oxidativ
160                                              Aldose reductase inhibition with fidarestat (16 mg . kg(
161 pathway, and PKCbetaII were all sensitive to aldose reductase inhibition.
162 lected from commercial databases for testing aldose reductase inhibition.
163 (butylated hydroxytoluene; 1% by diet) or an aldose reductase inhibitor (ARI) (sorbinil; 25 mg/kg/day
164 abetic rats were treated with or without the aldose reductase inhibitor (ARI) fidarestat (16 mg . kg(
165             ARI-809 is a recently discovered aldose reductase inhibitor (ARI) of a new structural cla
166 trol and galactose-fed rats treated with the aldose reductase inhibitor (ARI) Ponalrestat.
167 onic treatment with insulin or ICI222155, an aldose reductase inhibitor (ARI) previously shown to pre
168 erous attempts over 16 years, the results of aldose reductase inhibitor (ARI) trials for the treatmen
169  containing 50% galactose with or without an aldose reductase inhibitor (ARI) were investigated.
170                        Rats treated with the aldose reductase inhibitor AL01576 for the duration of t
171 se transporter inhibitor cytochalasin B, the aldose reductase inhibitor alrestatin, and the advanced
172                   Normal chow containing the aldose reductase inhibitor fidarestat (16 mg x kg(-1) x
173  the potential of vitamin K1 as a novel lens aldose reductase inhibitor in a streptozotocin-induced d
174                                          The aldose reductase inhibitor sorbinil (2.5 mg/ml) when add
175                   We then tested whether the aldose reductase inhibitor sorbinil and aspirin, which h
176 lglyoxal-treated HUVECs was prevented by the aldose reductase inhibitor sorbinil.
177 ecedented non-hydantoin, non-carboxylic acid aldose reductase inhibitor, 24, which shows remarkably p
178 abetic rats treated with a p38 inhibitor, an aldose reductase inhibitor, and insulin.
179 ly prevented by 12 weeks' treatment with the aldose reductase inhibitor, fidarestat.
180 on by sorbinil, a classic negatively charged aldose reductase inhibitor, results from binding to the
181                  The coadministration of the aldose reductase inhibitor, sorbinil, with 40 mM galacto
182 strating protection of ischemic hearts by an aldose reductase inhibitor, the presence and influence o
183                                              Aldose reductase inhibitors (ARIs) prevent peripheral ne
184 were treated with three structurally diverse aldose reductase inhibitors (ARIs).
185                                              Aldose reductase inhibitors (tolrestat or sorbinil) or a
186 es have demonstrated that negatively charged aldose reductase inhibitors act primarily by binding to
187                                  Insulin and aldose reductase inhibitors can prevent excess polyol pa
188 se results are confirmed in patient tissues, aldose reductase inhibitors could have some therapeutic
189 dependent manner by treating these dogs with aldose reductase inhibitors from the onset of galactosem
190                                              Aldose reductase inhibitors have shown promise in animal
191 group suggests an efficacious application of aldose reductase inhibitors in treating diabetic retinop
192 Reducing the polyol influx by treatment with aldose reductase inhibitors normalized intracellular sor
193                               Treatment with aldose reductase inhibitors or aldose reductase siRNA di
194 ent of vascular smooth muscle cells with the aldose reductase inhibitors tolrestat and sorbinil preve
195 ion of extant literature findings with other aldose reductase inhibitors, including zopolrestat, resu
196 zothiazol-2-yl)methyl]indole-N-alkanoic acid aldose reductase inhibitors.
197 ol in pericytes that was markedly reduced by aldose reductase inhibitors.
198 furoxane derivatives, 5a-k,m, synthesized as aldose reductase inhibitors.
199  the bioactive constituent possessing potent aldose reductase inhibitory action, with an IC50 value o
200 ity and alpha-amylase, alpha-glucosidase and aldose reductase inhibitory activity were assessed.
201 studies of the novel compounds clarified the aldose reductase inhibitory profile observed, thus ratio
202                 These findings indicate that aldose reductase is a component of ischemic injury and t
203               Recently, we demonstrated that aldose reductase is a component of myocardial ischemic i
204                                              Aldose reductase is also overexpressed in diabetic retin
205                               One product of aldose reductase is sorbitol, which has been linked to o
206 ctase, these results support the notion that aldose reductase is the key relay that converts hypergly
207  determine whether the polyol pathway enzyme aldose reductase mediates diabetes abnormalities in vasc
208               The present demonstration that aldose reductase mediates endotoxin-induced inflammation
209 GT1) and sodium-myo-inositol transporter and aldose reductase mRNA expression under hypertonic condit
210 s we report that the hypertonic induction of aldose reductase mRNA in HepG2 cells as well as the osmo
211 ibitors (tolrestat or sorbinil) or antisense aldose reductase mRNA prevented hyperproliferation of cu
212 in inhibition of the hypertonic induction of aldose reductase mRNA, ORE-driven reporter gene expressi
213             To rigorously test the effect of aldose reductase on myocardial ischemia-reperfusion inju
214                Pharmacological inhibition of aldose reductase or sorbitol dehydrogenase blocked JAK2
215           Specifically, the influence of the aldose reductase pathway flux on JAK-STAT signaling was
216                                          The aldose reductase pathway has been demonstrated to be a k
217  time, demonstrate JAK-STAT signaling by the aldose reductase pathway in ischemic hearts and is, in p
218 ctional recovery similar to that observed in aldose reductase pathway inhibited mice hearts.
219 cytosolic NADH/NAD+ ratio independent of the aldose reductase pathway inhibition, also blocked JAK2 a
220 vestigated signaling mechanisms by which the aldose reductase pathway mediates myocardial ischemic in
221 ucts; and increased glucose flux through the aldose reductase pathway.
222 tion of neutral endopeptidase, inhibition of aldose reductase plus lipoic acid supplementation, and i
223 njury and that pharmacological inhibitors of aldose reductase present a novel adjunctive approach for
224 ly, these results suggest that inhibition of aldose reductase prevents glucose-induced stimulation of
225 uciferase reporter gene construct containing aldose reductase promoter sequence from -1,094 base pair
226 and D-xylose), and a mutation in recombinant aldose reductase protein (C298A).
227  response to ischemia and that inhibition of aldose reductase reduces myocardial ischemic injury.
228                Pharmacological inhibition of aldose reductase significantly reduced ischemic injury a
229 reatment with aldose reductase inhibitors or aldose reductase siRNA did not affect mannitol-induced N
230                                     Both the aldose reductase specific inhibitor (zopolrestat) or tra
231                          In human platelets, aldose reductase synergistically modulated platelet resp
232 thione conjugate, which has to be reduced by aldose reductase to stimulate cell growth.
233 chieved by increased catalytic efficiency of aldose reductase toward hemithioacetal (product of gluta
234                                 Notably, the aldose reductase transcript was overexpressed in LHON cy
235 ivity and the osmotic stress response of rat aldose reductase transcription in a rat liver cell line,
236         However, the introduction of a human aldose reductase transgene into a GK-deficient backgroun
237 petitive to mixed type of inhibition of lens aldose reductase using Lineweaver Burk plot.
238                 With northern blot analysis, aldose reductase was detected in pericytes but not in en
239             Previously studied inhibitors of aldose reductase were largely from two chemical classes,
240 ndole-N-acetic acid (lidorestat, 9) inhibits aldose reductase with an IC(50) of 5 nM, while being 540
241  reductase)-null, cardiospecific-akr1b4 (rat aldose reductase), and akr1b8 (FR-1)-transgenic mice.
242 al cells (HUVECs) and C57 wild-type, akr1b3 (aldose reductase)-null, cardiospecific-akr1b4 (rat aldos
243  we investigated whether uric acid regulates aldose reductase, a key enzyme in the polyol pathway.
244                                              Aldose reductase, a member of the aldo-keto reductase fa
245 e of FR-1 shows striking homology with human aldose reductase, an enzyme linked to the pathogenesis o
246  probe vibration to the active site of human aldose reductase, and the response of the nitrile stretc
247 dehydrogenase flavoprotein [SDH Fp] subunit, aldose reductase, and TIM17 preprotein translocase); (4)
248 aracterize the kinetic properties of cardiac aldose reductase, as well as to study the impact of flux
249 ion of mRNA for hypertonicity-induced genes (aldose reductase, betaine/gamma-amino-n-butyric acid tra
250 enes of the aldo-keto reductase superfamily (aldose reductase, bile acid binder, and type I and type
251 romol/l zopolrestat, a specific inhibitor of aldose reductase, for 10 min, followed by 20 min of glob
252 , a function of renal medullary genes, e.g., aldose reductase, in diabetes.
253 ially docked to the expanded conformation of aldose reductase, known to bind larger ligands.
254  of inducible NO synthase, cyclooxygenase-2, aldose reductase, Mn superoxide dismutase, and probably
255 moprotective genes, including those encoding aldose reductase, Na+/Cl--coupled betaine/gamma-aminobut
256    When exposed to sorbinil, an inhibitor of aldose reductase, no GS-DHN was recovered in the coronar
257                    Sorbinil, an inhibitor of aldose reductase, prevented all abnormalities.
258  through hyperglycemia-induced activation of aldose reductase, reactive oxygen species, and c-Myc.
259 idney cortex characterized by high levels of aldose reductase, sorbitol and endogenous fructose.
260 studies have demonstrated that activation of aldose reductase, the first enzyme of the polyol pathway
261                              An inhibitor of aldose reductase, the rate-limiting enzyme in the pathwa
262                                              Aldose reductase, the rate-limiting enzyme of the polyol
263 09 is a novel chemotype highly selective for aldose reductase, these results support the notion that
264                                  Three genes-aldose reductase, thioredoxin reductase 1, and glucose-6
265 CD was also screened against the drug target aldose reductase, which can undergo large conformational
266 s pathway, we examined whether inhibition of aldose reductase, which catalyzes the first step of the
267  sepsis depend on the activity of the enzyme aldose reductase, which catalyzes the reduction of lipid
268 ly, these results suggest that inhibition of aldose reductase, which prevents PKC-dependent nonosmoti
269                                              Aldose reductase-catalyzed reduction is an important pat
270                 In this regard, we show that aldose reductase-deficient mice are protected against gl
271  metabolism of the GS-HNE conjugate involves aldose reductase-mediated reduction, a reaction catalyze
272 ction for the introduction of specificity to aldose reductase-targeted drugs.
273 e challenge were suppressed by inhibition of aldose reductase.
274 se related to metabolism of hexose sugars by aldose reductase.
275 the cavity sites and was especially true for aldose reductase.
276 ascular cell adhesion molecule (VCAM)-1, and aldose reductase.
277 undergoing apoptosis were immunoreactive for aldose reductase.
278 severe hyperglycemia and/or high activity of aldose reductase.
279  is most likely caused by S-nitrosylation of aldose reductase.
280 , sodium/chloride/betaine cotransporter, and aldose reductase.
281 e drug Alrestatin bound to a mutant of human aldose reductase.
282 cofactor binding characteristics observed in aldose reductase.
283 ion catalyzed in vitro by homogenous cardiac aldose reductase.
284 educe inflammatory responses downstream from aldose reductase.
285 including aquaporin-2, urea transporter, and aldose reductase.
286 se, xylose or arabinose) solution with a 4:1 aldose:sodium tetraborate molar ratio reacted with catal
287 e reactions, with no detectable admixture of aldoses, stands in stark contrast to the formose reactio
288 ediate required for the attack of the second aldose substrate, changing the chemistry from aldolase t
289                              A water-soluble aldose sugar dehydrogenase (Asd) has been purified for t
290 isplayed xylanase A, beta-xylosidase, and an aldose sugar dehydrogenase on Sup35(1-61) nanofibrils to
291 al and separate oxidation of xylose with the aldose sugar dehydrogenase, is more productive than an e
292 t into the characteristic anomeric carbon of aldose sugars and will facilitate the global analysis of
293           We find that, among all compounds, aldose sugars have the highest possible number of redox
294 irconium-catalyzed conversion of unprotected aldose sugars with acetylacetone to polyhydroxyalkyl fur
295  enzyme is able to act upon a broad range of aldose sugars, encompassing hexoses, pentoses, disacchar
296  but generic broad substrate specificity for aldose sugars.
297  reacts spontaneoulsy with ribose (and other aldoses) to give a mixture of four ribosides: alpha and
298 lysts are revealed: Bronsted acidity retards aldose-to-ketose isomerization by decreasing the equilib
299  pyridazinones, and has high selectivity for aldose versus aldehyde reductase.
300 g peracetylated furanoses directly from free aldoses was implemented.

 
Page Top